BridgeMD
New treatment option for Patients With an Abdominal Aortic Aneurysm of 39-49 mm in Diameter
Official title Alpha-Ketoglutarate and Abdominal Aortic Aneurysm Progression and Rupture
ClinicalTrials.gov ID: NCT04723888
What this study is testing
- What it's testing
- The objective of this project is to define whether nutritional supplement (oral administration with alpha-ketoglutarate) capable of filling-up the citric acid cycle (anaplerotic therapy) can improve outcomes in patients with an abdominal aortic aneurysm of 39-49 mm in diameter on ultrasound imaging. Alpha-ketoglutarate is commonly used as a nutritional supplement specially by athletes to increase muscle strength.
- Time commitment: about 5 years
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older
You may be able to join if
- Presence of an infrarenal AAA with a maximum diameter of 39-49 mm;
- Han nationality;
- Between 50 years or more, no gender limit;
- No mental illness;
- No history of supplement allergy or supplement allergy;
You likely can't join if
- Previous infrarenal aortic surgery;
- Planned major surgery;
- Known aortic dissection;
- Have received any other clinical trial treatment within 1 year;
- Systemic treatment with corticosteroids or other systemic immunomodulatory therapy;
- Severe infections, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.;
See the full eligibility criteria
- Presence of an infrarenal AAA with a maximum diameter of 39-49 mm;
- Han nationality;
- Between 50 years or more, no gender limit;
- No mental illness;
- No history of supplement allergy or supplement allergy;
- people voluntarily participate in this study, sign an informed consent form, have good compliance, and cooperate with follow-up.
- Previous infrarenal aortic surgery;
- Planned major surgery;
- Known aortic dissection;
- Have received any other clinical trial treatment within 1 year;
- Systemic treatment with corticosteroids or other systemic immunomodulatory therapy;
- Severe infections, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.;
- Known or suspected inherited connective tissue disorder;
- Calculated creatinine clearance of less than 30 ml/min;
- Known significant liver disease;
- Known human immunodeficiency virus infection at the time of screening；
- Serious concomitant illness associated with life expectancy of less than 2 years；
- Any other significant and unstable condition that could limit compliance with the trial protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 5 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.